natgillin/translations-raw huggingface dataset:
Fractures are often bilateral; therefore the contralateral femur should be examined in bisphosphonate-treated patients who have sustained a femoral shaft fracture. 
Budući da su prijelomi često obostrani, u bolesnika liječenih bisfosfonatima s prijelomom dijafize bedrene kosti potrebno je pregledati bedrenu kost na suprotnoj strani.
BPI mean change from baseline 
Srednja vrijednost promjene BPI od početne vrijednosti
Treatment of TIH 
NAČIN PRIMJENE LIJEKA
Zoledronic acid does not inhibit human P450 enzymes in vitro, shows no biotransformation and in animal studies < 3% of the administered dose was recovered in the faeces, suggesting no relevant role of liver function in the pharmacokinetics of zoledronic acid. 
<3% primijenjene doze otkrilo se u izmetu, što pokazuje da funkcija jetre nema važnu ulogu u farmakokinetici zoledronatne kiseline.
Withdraw an appropriate volume of the reconstituted solution (4 mg/5 ml) as needed: - 4.4 ml for 3.5 mg dose 
Izvucite sljedeći odgovarajući volumen rekonstituirane otopine (4 mg/5 ml), kako slijedi: - 4,4 ml za dozu od 3,5 mg
Do not mix Zometa reconstituted solution with calcium-containing or other divalent cation-containing solutions such as lactated Ringer's solution. 
Rekonstituirana otopina Zomete ne smije se miješati s otopinama koje sadrže kalcij ili druge dvovalentne katione kao što je Ringerova otopina s laktatom.
Multipack comprising ten packs, each containing one vial. 
Višestruko pakiranje koje se sastoji od deset pakiranja, od kojih svako sadrži po jednu bočicu.
Zometa 4 mg powder and solvent for solution for infusion zoledronic acid 
Zometa 4 mg prašak i otapalo za otopinu za infuziju zoledronatna kiselina
Gastrointestinal disorders Very common: 
Poremećaji probavnog sustava Vrlo često:
Osteonecrosis of the jaw 
Osteonekroza čeljusti
FOLDING BOX FOR 1 VIAL AND 1 AMPOULE AS UNIT PACK (INCLUDING BLUE BOX) FOLDING BOX FOR 4 VIALS AND 4 AMPOULES AS UNIT PACK (INCLUDING BLUE BOX 
KUTIJA ZA 4 BOČICE I 4 AMPULE KAO JEDINIČNO PAKIRANJE (UKLJUČUJUĆI PLAVI OKVIR)
How much Zometa is given - The usual single dose given is 4 mg. - If you have a kidney problem, your doctor will give you a lower dose depending on the severity of your kidney problem. 
- Ako imate tegobe s bubrezima, liječnik će Vam dati nižu dozu ovisno o težini tegoba koje imate s bubrezima.
LABELLING AND PACKAGE LEAFLET 
Kako Zometa izgleda i sadržaj pakiranja
Skeletal morbidity rate p-value 
Stopa koštanog pobola 1,04 p-vrijednosti
The adverse reactions ranked under headings of frequency, are presented in Table 6. 
Nuspojave navedene prema učestalosti prikazane su u Tablici
Uncommon (may affect up to 1 in 100 people): 
Manje često (može se javiti u do 1 na 100 osoba):
Atypical fractures of the femur 
Atipični prijelomi bedrene kosti
Sodium citrate Water for injections 
6.1 Popis pomoćnih tvari manitol natrijev citrat voda za injekcije
1 bottle contains 4 mg zoledronic acid, corresponding to 4.264 mg zoledronic acid monohydrate. 
1 boca sadrži 4 mg zoledronatne kiseline, što odgovara 4,264 mg zoledronatne kiseline hidrata.
One bottle contains 4 mg zoledronic acid, corresponding to 4.264 mg zoledronic acid monohydrate. 
Jedna boca sadrži 4 mg zoledronatne kiseline, što odgovara 4,264 mg zoledronatne kiseline hidrata.
Contact your doctor if you experience pain, weakness or discomfort in your thigh, hip or groin as this may be an early indication of a possible fracture of the thigh bone. 
Rijetko može nastati neuobičajen prijelom bedrene kosti osobito u bolesnika koji se dugotrajno liječe zbog osteoporoze; osjetite li bol, slabost ili nelagodu u natkoljenici, kuku ili preponama, odmah se javite liječniku, jer to mogu biti rani znakovi mogućeg prijeloma bedrene kosti.
How Zometa is used 
Koliko se često daje Zometa
Renal function impairment 
Oštećenje funkcije bubrega
Proportion of patients with SREs (%) p-value 
Udio bolesnika s koštanim događajem p-vrijednost Medijan vremena do koštanog događaja (dani)
AMPOULE LABEL 
Prijavljivanje nuspojava
Pruritus, rash (including erythematous and macular rash), increased sweating 
Svrbež, osip (uključujući eritematozni i makularni osip), pojačano znojenje Poremećaji mišićno-koštanog sustava i vezivnog tkiva Često:
One vial contains 4 mg zoledronic acid, corresponding to 4.264 mg zoledronic acid monohydrate. 
Jedna bočica sadrži 4 mg zoledronatne kiseline, što odgovara 4,264 mg zoledronatne kiseline hidrata.
This summary was last updated in June 2014. 
Sažetak je posljednji put dopunjen u lipnju 2014.
The measure of effectiveness was levels of antibodies before and after vaccination. 
Mjera djelotvornosti bila je razina protutijela prije i nakon cijepljenja.
Vaccines work by ‘teaching' the immune system (the body's natural defences) how to defend itself against a disease. 
Cjepivo djeluje „učeći” imunosni sustav (prirodnu obranu tijela) kako da se brani protiv bolesti.
Responses in puppies were lower than adult dogs in some cases, because of antibodies inherited from their mothers. 
Odgovor u štenadi je bio manji nego u odraslih pasa u pojedinim slučajevima, budući da se protutijela nasljeđuju od majki.
The dogs were either vaccinated twice with a three or four week interval or they received a single annual booster vaccination. 
Psi su cijepljeni dva puta u razmaku od tri ili četiri tjedna ili su docijepljeni jednim godišnjim booster cjepivom.
In situations where puppies are expected to inherit very high antibody levels from the bitch the vaccination protocol should be planned accordingly. 
U situacijama kada se očekuje da će štenad naslijediti visoke razine protutijela od kujice, potrebno je primjereno planirati protokol cijepljenja.
If you want more information on the basis of the CVMP recommendations, read the scientific discussion (also part of the EPAR). 
Ako želite više informacija na temelju preporuka Odbora za veterinarsko-medicinske proizvode (CVMP), pročitajte znanstvenu raspravu (ista je dio Europskoga javnog izvješća o procjeni veterinarsko-medicinskog proizvoda (EPAR)).
In the future, if the animals are exposed to these viruses or bacteria again the immune system will be able to respond more quickly. 
Ubuduće ako se životinje izlože ovim infekcijama, imunosni sustav će brže stvarati protutijela.
This will help protect them against kennel cough and leptospirosis. 
Ovo pomaže pri njihovoj zaštiti od kašlja čopora i leptospiroze.
The field study showed that after vaccination with Versican Plus Pi/L4 the percentage of dogs with protective levels of antibodies for parainfluenza virus ranged from 73 to 97% and for leptospira 59 to 96%. 
Terenskim je ispitivanjem dokazano da se nakon cijepljenja cjepivom Versican Plus Pi/L4 postotak pasa sa zaštitnim razinama protutijela za virusa parainfluence kretao od 73 do 97%, za leptospiru od 59 do 96%.
The European Commission granted a marketing authorisation valid throughout the European Union, for Versican Plus Pi/L4 on 31 July 2014. 
Europska komisija dodijelila je odobrenje za stavljanje u promet koje je na snazi na teritoriju Europske unije za proizvod Versican Plus Pi/L4 od 31. srpnja 2014.
The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Versican Plus Pi/L4 exceed the risks for the approved indications and recommended that Versican Plus Pi/L4 be given a marketing authorisation. 
Odbor za veterinarsko-medicinske proizvode (CVMP) zaključio je da koristi lijeka Versican Plus Pi/L4 nadmašuju rizike za odobrene indikacije i preporučilo je izdavanje odobrenja za stavljanje u promet VMP-a Versican Plus Pi/L4.
The effectiveness of Versican Plus Pi/L4 was investigated in a field study involving 129 dogs. 
Djelotvornost cjepiva Versican Plus Pi/L4 ispitana je terenskim ispitivanjem koje je obuhvatilo 129 pasa.
Versican Plus Pi/L4 is a veterinary vaccine that contains live attenuated (weakened) canine parainfluenza virus type 2 as well as inactivated (killed) strains of Leptospira bacteria (Icterohaemorrhagiae, Canicola, Bratislava and Grippotyphosa). 
Versican Plus Pi/L4 je veterinarsko cjepivo koje sadrži živi atenuirani (oslabljeni) virus pseće parainfluence tip 2 kao i inaktivirane (ubijene) sojeve bakterije Leptospira (Icterohaemorrhagiae, Canicola, Bratislava i Grippotyphosa).
In case of accidental self-injection, medical advice should be sought immediately and the package leaflet or label shown to the doctor. 
U slučaju da se nehotice samo injicira, odmah potražiti pomoć liječnika i pokažite mu uputu o VMP ili etiketu.
• canine parainfluenza virus, which causes kennel cough; 
• virusa pseće parainfluence, koji uzrokuje kašalj čopora;
When Versican Plus Pi/L4 is given to dogs the animals' immune system recognises the viruses and bacteria as ‘foreign' and makes antibodies against them. 
U slučaju kada se Versican Plus Pi/L4 primjenjuje u pasa, imunosni sustav životinje prepoznaje viruse i bakterije kao „strane” i proizvodi protutijela protiv virusa i bakterija.
The benefit-risk balance may be found in the scientific discussion module of this EPAR. 
Omjer koristi i rizika dostupan je u modulu znanstvene rasprave ovog EPAR-a.
The canine parainfluenza virus in Versican Plus Pi/L4 is alive but has been attenuated (weakened) so that it does not cause disease; it is combined with killed (inactivated) strains of Leptospira bacteria. 
Virus pseće parainfluence u cjepivu Versican Plus Pi/L4 je živ, ali je atenuiran (oslabljen) tako da ne uzrokuje bolest; kombiniran je s ubijenim (inaktiviranim) sojevima bakterije Leptospira.
Versican Plus Pi/L4 contains an adjuvant (aluminium hydroxide) to enhance the immune response. 
Versican Plus Pi/L4 sadrži adjuvans (aluminijev hidroksid) kako bi se pojačao imunosni odgovor.
Canine parainfluenza virus (live attenuated) and canine leptospirosis (inactivated) vaccine 
Virus pseće parainfluence (živi atenuirani) i cjepivo protiv pseće leptospiroze (inaktivirano)
Versican Plus Pi/L4 is used to protect dogs against: 
Versican Plus Pi/L4R se koristi za zaštitu pasa od:
The most common side effect (seen in more than 1 in 100 dogs) with Versican Plus Pi/L4 is a short lived swelling of up to 5 cm which may occur at the injection site after vaccination. 
Najčešće nuspojave (kod 1 od 100 pasa) lijeka Versican Plus Pi/L4 isu kratkotrajno oticanje do 5 cm koje može nastupiti na mjestu injekcije nakon cijepljenja.
For revaccination a single dose of Versican Plus Pi/L4 is required annually. 
Za docjepljivanje potrebna je jedna doza cjepiva Versican Plus Pi/L4 godišnje.
Versican Plus Pi/L4 is a vaccine. 
Versican Plus Pi/L4 je cjepivo.
Versican Plus Pi/L4 is available as a lyophilisate (freeze-dried pellet) with solvent for injection. 
Versican Plus Pi/L4 dostupan je kao liofilizat (smrzavanjem osušen pelet) s otapalom za injekciju.
Other information about Versican Plus Pi/L4: 
Druge informacije o Versican Plus Pi/L4:
What is the risk associated with Versican Plus Pi/L4? 
Koji su rizici povezani s Versican Plus Pi/L4?
What is Versican Plus Pi/L4? 
Što je Versican Plus Pi/L4?
Why has Versican Plus Pi/L4 been approved? 
Zašto je Versican Plus Pi/L4R odobren?
What benefit has Versican Plus Pi/L4 shown during the studies? 
Koje koristi Versican Plus Pi/L4 su utvrđene tijekom ispitivanja?
How has Versican Plus Pi/L4 been studied? 
Kako se Versican Plus Pi/L4 ispitivao?
What is Versican Plus Pi/L4 used for? 
Za što se Versican Plus Pi/L4 koristi?
The vaccine is given to puppies from six weeks of age as an injection, under the skin, and repeated three to four weeks later. 
• leptospiroze, bakterijske bolesti koja se može prenijeti putem zaraženog urina, a rezultira krvarenjem, hepatitisom (upalom jetre) i žuticom ili nefritisom (upalom bubrega); Cjepivo se primjenjuje u štenadi u dobi od šest tjedana u obliku supkutane injekcije i ponavlja se nakon tri do četiri tjedana.
How does Versican Plus Pi/L4 work? 
Na koji način Versican Plus Pi/L4 djeluje?
This summary was last updated in 09-2017. 
Sažetak je posljednji put ažuriran: 09. 2017.
The recommended dose is one 150 microgram capsule, once a day at the same time each day. 
Preporučena doza je jedna kapsula od 150 mikrograma, jednom dnevno u isto vrijeme svakog dana.
The main measure of effectiveness was based on changes in the patients' forced expiratory volumes (FEV1, the maximum volume of air a person can breathe out in one second) after 12 weeks. 
Glavna mjera djelotvornosti temeljila se na promjenama forsiranog izdisajnog volumena u bolesnika (FEV1, maksimalni volumen zraka koji osoba može izdahnuti u jednoj sekundi) nakon 12 tjedana.
The full EPAR for Onbrez Breezhaler can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Cjeloviti EPAR za lijek Onbrez Breezhaler nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
It works by attaching to beta-2 receptors that are found in the muscle cells of many organs and that cause the muscles to relax. 
Djeluje tako što se veže na beta-2 receptore koji se nalaze u mišićnim stanicama mnogih organa, a to dovodi do opuštanja mišića.
This causes the muscles of the airways to relax, helping to keep the airways open and allowing the patient to breathe more easily. 
To dovodi do opuštanja mišića dišnih putova, što pomaže održati dišne putove otvorenima i omogućava bolesniku lakše disanje.
The increase in FEV1 was 130 ml with tiotropium, and 80 ml with formoterol. 
Povećanje vrijednosti FEV1 iznosilo je 130 ml uz primjenu tiotropija i 80 ml uz formoterol.
Overall, the effects of the 150 and 300 microgram doses of Onbrez Breezhaler were similar, but the results showed that the 300 microgram dose may provide better relief in patients with more severe disease. 
Sveukupno, učinci doza lijeka Onbrez Breezhaler od 150 i 300 mikrograma bili su slični, ali rezultati su pokazali da bolesnicima s težom bolesti veće olakšanje može pružiti doza od 300 mikrograma.
The medicine contains the active substance indacaterol. 
Lijek sadržava djelatnu tvar indakaterol.
To receive a dose, the patient places a capsule into the inhaler and breathes the powder in through the mouth. 
Kako bi uzeli potrebnu dozu, bolesnici trebaju staviti kapsulu u inhalator i kroz usta udahnuti prašak iz kapsule.
COPD is a long-term disease in which the airways and air sacs inside the lungs become damaged or blocked, leading to difficulty breathing. 
KOPB je dugotrajna bolest kod koje su dišni putovi i plućni mjehurići oštećeni ili začepljeni, što dovodi do otežanog disanja.
In three main studies involving over 4,000 patients with COPD, Onbrez Breezhaler was compared with placebo (a dummy treatment), tiotropium or formoterol (other inhaled medicines used to treat COPD). 
U tri glavna ispitivanja koja su obuhvatila više od 4000 bolesnika s KOPB-om, Onbrez Breezhaler uspoređen je s placebom (prividno liječenje), tiotropijem ili formoterolom (drugi lijekovi za inhalaciju kojima se liječi KOPB).
Other common side effects include chest pain, cough and muscle cramps. 
Druge česte nuspojave uključuju bol u prsnom košu, kašalj i grčeve mišića.
On average, the increase in FEV1 in patients who received Onbrez Breezhaler was between 150 to 190 ml, while for patients who received placebo the change in FEV1 ranged from a decrease of 10 ml to an increase of 20 ml. 
Povećanje vrijednosti FEV1 u bolesnika koji su primili Onbrez Breezhaler iznosilo je u prosjeku između 150 i 190 ml, dok se u bolesnika koji su primali placebo promjena FEV1 kretala u rasponu od smanjenja od 10 ml do povećanja od 20 ml.
The most common side effects with Onbrez Breezhaler (which may affect more than 1 in 10 people) are nasopharyngitis (inflammation of the nose and throat) and upper respiratory tract infection (infection of the nose and throat). 
Najčešće nuspojave lijeka Onbrez Breezhaler (koje se mogu javiti u više od 1 na 10 osoba) jesu nazofaringitis (upala nosa i grla) i infekcija gornjeg dišnog sustava (infekcija nosa i grla).
This is a summary of the European public assessment report (EPAR) for Onbrez Breezhaler. 
Ovo je sažetak europskoga javnog izvješća o procjeni (EPAR) lijeka Onbrez Breezhaler.
Onbrez Breezhaler is used for maintenance (regular) treatment. 
Onbrez Breezhaler primjenjuje se za (redovitu) terapiju održavanja.
European Commission granted a marketing authorisation valid throughout the European Union for Onbrez Breezhaler on 30 November 2009. 
Europska komisija izdala je odobrenje za stavljanje lijeka Onbrez Breezhaler u promet koje vrijedi na prostoru Europske unije od 30. studenoga 2009.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Onbrez Breezhaler have been included in the summary of product characteristics and the package leaflet. 
Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Onbrez Breezhaler nalaze se u sažetku opisa svojstava lijeka i u uputi o lijeku.
Onbrez Breezhaler capsules, which contain a power for inhalation, are only used with a Onbrez Breezhaler inhaler and must not be swallowed. 
Kapsule lijeka Onbrez Breezhaler, koje sadržavaju prašak inhalata, primjenjuju se samo s inhalatorom za Onbrez Breezhaler i ne smiju se progutati.
Therefore, the Agency decided that Onbrez Breezhaler's benefits are greater than its risks and recommended that it be given marketing authorisation. 
Agencija je stoga odlučila da koristi lijeka Onbrez Breezhaler nadmašuju s njim povezane rizike te je preporučila izdavanje odobrenja za stavljanje lijeka u promet.
Onbrez Breezhaler is a medicine that is used to keep the airways open in adults with chronic obstructive pulmonary disease (COPD). 
Onbrez Breezhaler je lijek koji se primjenjuje kako bi se dišne putove u odraslih bolesnika s kroničnom opstruktivnom plućnom bolesti (KOPB) držalo otvorenima.
The European Medicines Agency concluded that Onbrez Breezhaler was shown to be effective at improving the lung function in COPD. 
Europska agencija za lijekove zaključila je da se Onbrez Breezhaler pokazao učinkovitim u poboljšanju funkcije pluća kod KOPB-a.
The Agency also noted that there were no major safety concerns with Onbrez Breezhaler, with side effects being manageable and similar to other beta-2 adrenergic receptor agonist medicines. 
Agencija je također zaključila da nisu ustanovljeni razlozi za ozbiljnu zabrinutost u pogledu sigurnosti lijeka Onbrez Breezhaler te da se nuspojave mogu liječiti i slične su onima drugih agonista beta-2 adrenergičkih receptora.
What measures are being taken to ensure the safe and effective use of Onbrez Breezhaler? 
Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Onbrez Breezhaler?
The active substance in Onbrez Breezhaler, indacaterol, is a beta-2 adrenergic receptor agonist. 
Djelatna tvar lijeka Onbrez Breezhaler je indakaterol, agonist beta-2 adrenergičkih receptora.
For more information about treatment with Onbrez Breezhaler, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Više informacija o liječenju lijekom Onbrez Breezhaler pročitajte u uputi o lijeku (također dio EPAR-a), odnosno obratite se svom liječniku ili ljekarniku.
Onbrez Breezhaler was more effective than placebo at improving how well the lungs work in patients with COPD. 
Onbrez Breezhaler pokazao se učinkovitijim od placeba u poboljšanju rada pluća u bolesnika s KOPB-om.
When Onbrez Breezhaler is inhaled, indacaterol reaches the receptors in the airways and activates them. 
Udisanjem lijeka Onbrez Breezhaler, indakaterol dospijeva do receptora u dišnim putovima i aktivira ih.
Onbrez Breezhaler indacaterol 
Onbrez Breezhaler indakaterol
What is Onbrez Breezhaler and what is it used for? 
Što je Onbrez Breezhaler i za što se koristi?
The doctor may increase the dose to one 300 microgram capsule once a day in cases of severe COPD. 
U slučaju teškog KOPB-a, liječnik može povećati dozu na jednu kapsulu od 300 mikrograma jednom dnevno.
For practical information about using Onbrez Breezhaler, patients should read the package leaflet or contact their doctor or pharmacist. 
Praktične informacije o primjeni lijeka Onbrez Breezhaler bolesnici trebaju pročitati u uputi o lijeku, odnosno trebaju se obratiti svom liječniku ili ljekarniku.
It is not intended to provide practical advice on how to use Onbrez Breezhaler. 
Svrha sažetka nije davati praktične savjete o primjeni lijeka Onbrez Breezhaler.
Other information about Onbrez Breezhaler 
Ostale informacije o lijeku Onbrez Breezhaler
What are the risks associated with Onbrez Breezhaler? 
Koji su rizici povezani s lijekom Onbrez Breezhaler?
For the full list of all side effects and restrictions with Onbrez Breezhaler, see the package leaflet. 
Potpuni popis svih nuspojava i ograničenja pri primjeni lijeka Onbrez Breezhaler potražite u uputi o lijeku.
Why is Onbrez Breezhaler approved? 
Zašto je lijek Onbrez Breezhaler odobren?
How is Onbrez Breezhaler used? 
Kako se Onbrez Breezhaler koristi?
How does Onbrez Breezhaler work? 
Kako djeluje Onbrez Breezhaler?
What benefits of Onbrez Breezhaler have been shown in studies? 
Koje su koristi lijeka Onbrez Breezhaler utvrđene u ispitivanjima?
Their frequency is unknown. 
Njihova učestalost nije poznata.
The expressed juice may then be dried. 
Istisnuti sok se zatim može osušiti.
This means that there are bibliographic data providing scientific evidence of their effectiveness and safety when used in this way, covering a period of at least 10 years in the EU. 
To znači da postoje bibliografski podaci koji pružaju znanstvene dokaze o njihovoj učinkovitoj i sigurnoj primjeni kada se koriste na opisani način, a pokrivaju razdoblje od najmanje 10 godina u EU.
The flowering aerial parts for medicinal uses are obtained from plants that have been cultivated or found in the wild. 
Cvjetajući nadzemni dijelovi za medicinsku uporabu dobivaju se iz biljaka koje su kultivirane ili pronađene u divljini.
This means that, although there is insufficient evidence from clinical trials, the effectiveness of these herbal medicines is plausible and there is evidence that they have been used safely in this way for at least 30 years (including at least 15 years within the EU). 
To znači da, iako postoji nedovoljno dokaza iz kliničkih ispitivanja, učinkovitost ovih biljnih lijekova je vjerojatna i postoje dokazi o njihovoj sigurnoj primjeni na opisani način najmanje 30 godina (uključujući najmanje 15 godina u EU).
When used for prevention and treatment of common cold, cases of serious allergic reactions (such as Stevens-Johnson syndrome, asthma and anaphylactic shock) have been reported, especially in patients who are atopic (have a predisposition to allergic reactions). 
Prilikom primjene za sprječavanje i liječenje prehlade, zabilježeni su slučajevi ozbiljnih alergijskih reakcija (poput Stevens-Johnsonovog sindroma, astme i anafilaktičkog šoka), posebice u bolesnika koji su atopičari (imaju predispoziciju na alergijske reakcije).
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom persist for more than one week. 
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom20. listopada 2015. EMA/481797/2015
However, these data were insufficient to be used as evidence of effectiveness and the HMPC conclusions for this indication are based on the medicines' long-standing use. 
No, ovi podaci su nedostatni da bi se koristili kao dokaz o učinkovitosti, te je HMPC temeljio svoje zaključke za ovu indikaciju na dugotrajnoj uporabi lijekova.
The HMPC noted possible beneficial effects on wound healing in animal studies. 
HMPC je naveo moguće korisno djelovanje na zarastanje rana u ispitivanjima na životinjama.
Purple coneflower herb medicines should only be used in adults and adolescents above the age of 12 years. 
Lijekovi koji sadrže zelen purpurne rudbekije smiju se koristiti samo u odraslih osoba i adolescenata starijih od 12 godina.
For further information on the studies assessed by the HMPC, see the HMPC assessment report. 
Za podrobnije informacije o ispitivanjima koje je HMPC ocijenio pogledajte izvješće HMPC-a o ocjeni lijeka.